Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles

Archives of Medical Science

Volumn 6, Issue 6, 2010, Pages 945-949

  Tehraninejad, Ensieh Sh ^a,b   Nekoo, Elham Azimi ^b   Ezabadi, Zahra ^a   Rashidi, Batool H ^b   Amirchaghmaghi, Elham ^a   Matroud, Elham Pour ^b  

^a ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Assisted reproductive technology; Diphereline; GnRH agonist; Half dose

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HUMAN MENOPAUSAL GONADOTROPIN; MONOGON; PROGESTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED OVARIAN STIMULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONAL REGULATION; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OVARY FUNCTION; OVARY HYPERSTIMULATION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 78751475562     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.19306     Document Type: Article

References (16)

1. Gemzell CA, Kemman E, Jones JR. Premature ovulation during administration of hMG in nonovulatory women. Infertility 1998; 1: 1-10.
2. Testart J, Lefevre B, Gougeon A. Effects of gonadotrophin releasing hormone agonists (GnRHa) on follicle and oocyte quality. Hum Reprod 1993; 8: 511-8.
3. Tapanainen J, Hovatta O, Juntunen K, et al. Subcutaneous goserelin versus intranasal buserelin for pituitary downregulation in patients undergoing IVF: A randomized comparative study. Hum Reprod 1993; 8: 2052-5.
4. Taheripanah R, Karimzadeh MA, Ghafourzadeh M. Efficacy of Low Dose, Long-acting Gonadotropin Releasing Hormone Analogues (GnRH-a) Compared with Daily Injections of Short-acting GnRH-a in ART Cycles. Iranian Journal of Reproductive Medicine 2004; 2: 29-33.
5. Oyesanya OA, Teo SK, Quah E, Abdurazak N, Lee FY, Cheng WC. Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: A comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact Hum Reprod 1995; 10: 1042-4.
6. Dal Prato L, Borini A, Coticchio G, Cattoli M, Flamigni C. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: A randomized study. Hum Reprod 2004; 19: 2200-5.
7. Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev 2005; 1.
8. Gonen Y, Dirnfeld M, Goldman S, Koifman M, Abramovici H. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF). J In Vitro Fert Embryo Transf 1991; 8: 254-9.
9. Cheon KW, Song SJ, Choi BC, et al. Comparison of clinical efficacy between a single administration of long-acting gonadotrophin-releasing hormone agonist (GnRHa) and daily administrations of short-acting GnRHa in in vitro fertilization-embryo transfer cycles. J Korean Med Sci 2008; 23: 662-6.
10. Balasch J, Gomez F, Casamitjana R, Carmona F, Rivera F, Vanrell JA. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum Reprod 1992; 7: 1230-4.
11. Yim SF, Lok IH, Cheung LP, Briton-Jones CM, Chiu TT, Haines CJ. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF. Hum Reprod 2001; 16: 492-4.
12. Tsai HD, Chen CM, Lo HY, Chang CC. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Hum Reprod 1995; 10: 2909-12.
13. Hsieh Y, Tsai H, Chang C, Chang C, Lo H. Comparison of a single half-dose, longacting form of gonadotropinreleasing hormone analog (GnRH-a) and a short acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program. Fertil Steril 2000; 73: 817-20.
14. Conaghan, J, Hardy, K, Handyside AH, Winston R, Leese H. Selection criteria for human embryo transfer: A comparison of pyruvate uptake and morphology. J Assist Reprod Genet 1993; 10: 21-30.
15. Gomes LM, Canha Ados S, Dzik A, Novo NF, Juliano Y, Dos Santos SI, Cavagna M.The age as a predictive factor in in vitro fertilization cycles. Rev Bras Ginecol Obstet 2009; 31: 230-4.
16. Safdarian L, Soltani Mohammadi F, Alleyassin A, Aghahosseini M, Alipasha M , Rahimi E. Clinical outcome with half-dose depot triptorelin is the same as reduceddose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI /embryo transfer: A randomized double-blind clinical trial (NCT00461916). Hum Reprod 2007; 22: 2449-54.